Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems.
Jung-Im ShinYunwen XuAlexander R ChangJuan J CarreroCarina M FlahertyAmrita MukhopadhyayLesley A InkerSaul B BleckerLeora I HorwitzMorgan E GramsPublished in: Journal of the American College of Cardiology (2024)
In this analysis of U.S. data from 2022 to 2023, SGLT2 inhibitor prescription among people with a Class 1a recommendation is low. Interventions are needed to increase uptake of guideline-recommended SGLT2 inhibitor use.